Key Points
- CEO Kathy Lee-Sepsick purchased 15,625 Femasys shares at $3.20 each, investing $50,000 and becoming the direct owner of those shares.
- Femasys shares opened at $2.35, near their 12-month low of $2.29 and substantially below the 12-month high of $22.20. The company has a market capitalization of approximately $7.1 million.
- Analyst sentiment is mixed, with two Buy ratings and one Sell rating resulting in an average Hold rating. Institutional investors and hedge funds own 65.27% of the company.
Femasys Inc. (NASDAQ:FEMY - Get Free Report) COO John Charles Canning purchased 4,375 shares of the business's stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $14,000.00. Following the acquisition, the chief operating officer owned 4,375 shares of the company's stock, valued at approximately $14,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Femasys Stock Performance
Shares of NASDAQ FEMY opened at $2.35 on Wednesday. Femasys Inc. has a 12-month low of $2.29 and a 12-month high of $22.20. The company has a market cap of $7.10 million, a PE ratio of -0.44 and a beta of -2.08. The stock has a 50 day simple moving average of $3.87 and a 200-day simple moving average of $7.49. The company has a current ratio of 3.91, a quick ratio of 1.98 and a debt-to-equity ratio of 0.53.
Institutional Trading of Femasys
A number of hedge funds and other institutional investors have recently modified their holdings of FEMY. State Street Corp lifted its holdings in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company's stock valued at $47,000 after buying an additional 24,500 shares during the period. Kovack Advisors Inc. bought a new stake in Femasys in the fourth quarter worth about $27,000. Osaic Holdings Inc. bought a new stake in Femasys in the second quarter worth about $45,000. HRT Financial LP acquired a new stake in Femasys in the 4th quarter valued at about $30,000. Finally, Cetera Investment Advisers acquired a new stake in Femasys in the 4th quarter valued at about $36,000. Institutional investors own 65.27% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on FEMY. Wall Street Zen upgraded Femasys to a "hold" rating in a research report on Saturday, June 13th. Weiss Ratings raised Femasys from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, July 31st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $80.00.
Check Out Our Latest Stock Analysis on FEMY
Femasys Company Profile
(
Get Free Report)
Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women's health applications. The company's core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.
The company's flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
